Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,187
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
-, Apalutamide placebo, JNJ-56021927
Janssen-Cilag International N.V.
Metastatic Hormone-sensitive Prostate Cancer
1 trial -
-, TECHNETIUM (99MTC) COMPOUNDS, -, JNJ-56021927
Janssen-Cilag International N.V.
High risk recurrent prostate cancer previously treated with radical prostatectomy
1 trial -
ABIRATERONE , DEGARELIX , Niraparib - capsule - 100 mg, RELUGOLIX , Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, Placebo for Niraparib, Prednison acis 5 mg, Tabletten, Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, TECHNETIUM (99MTC) COMPOUNDS, -, Abiraterone acetate - tablet - 250 mg
Janssen-Cilag International N.V.
Metastatic Prostate Cancer
1 trial -
BCG VACCINE , JNJ-63723283, JNJ-17000139, JNJ-63723283
Janssen-Cilag International N.V.
High-Risk Non-muscle-invasive Bladder Cancer
1 trial -
CARBOPLATIN , FLUOROURACIL , JNJ-61186372, CISPLATIN , PEMBROLIZUMAB
Janssen-Cilag International N.V.
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
1 trial -
Dexamethasone Tablets BP 2.0mg, Fortecortin® 2 mg Tabletten, Lenalidomide Accord 15 mg hard capsules, CARVYKTI 3.2 × 10^6 – 1.0 × 10^8 cells dispersion for infusion, Lenalidomide Mylan 5 mg hard capsules, Lenalidomide Mylan 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Mylan 20 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 2.5 mg hard capsules, FLUDARABINE , Lenalidomide Mylan 15 mg hard capsules, Lenalidomide Accord 10 mg hard capsules
Janssen-Cilag International N.V.
Multiple Myeloma
1 trial -
EFGARTIGIMOD ALFA, JNJ-80202135
Janssen-Cilag International N.V.
generalized myasthenia gravis
1 trial -
Enbrel 50 mg solution for injection in pre-filled syringe, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 1 mL PFS Placebo, Guselkumab, Guselkumab 0.5 mL Varioject Placebo, Enbrel 25 mg powder and solvent for solution for injection
Janssen-Cilag International N.V.
Chronic Plaque Psoriasis
1 trial -
Erbitux 5 mg/mL solution for infusion, JNJ-61186372, Erbitux 5 mg/mL solution for infusion, VEGZELMA 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., BEVACIZUMAB
Janssen-Cilag International N.V.
KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer
1 trial -
Film-Coated Tablet without Deucravacitinib, Film-Coated Tablet without JNJ-77242113, DEUCRAVACITINIB, JNJ-77242113
Janssen-Cilag International N.V.
Moderate to Severe Plaque Psoriasis
1 trial -
Film-Coated Tablet without JNJ-77242113, JNJ-77242113
Janssen-Cilag International N.V.
Plaque Psoriasis
1 trial -
Fortecortin® 2 mg Tabletten, Privigen 100 mg/ml solution for infusion, Privigen 100 mg/ml solution for infusion, KIOVIG 100 mg/ml solution for infusion, Imnovid 4 mg hard capsules, Privigen 100 mg/ml solution for infusion, Pomalidomide, KIOVIG 100 mg/ml solution for infusion, Imnovid 1 mg hard capsules, KIOVIG 100 mg/ml solution for infusion, Pomalidomide, Dexamethasone Tablets BP 2.0mg, JNJ-64407564, JNJ-64407564, Pomalidomide, DARZALEX 1800 mg solution for injection, Imnovid 3 mg hard capsules, Dexamethas
Janssen-Cilag International N.V.
Relapsed or Refractory Multiple Myeloma
1 trial -
Fortecortin® 2 mg Tabletten, teclistamab, Lenalidomide Mylan 25 mg hard capsules, JNJ-64407564, Dexamethasone Tablets BP 2.0mg, Lenalidomide Accord 10 mg hard capsules, JNJ-64407564, Lenalidomide Mylan 15 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Lenalidomide Mylan 5 mg hard capsules, Privigen 100 mg/ml solution for infusion, DARZALEX 1800 mg solution for injection, Lenalidomide Accord 15 mg hard capsules, Lenalidomide Accord 25 mg hard capsules, Privigen 100 mg
Janssen-Cilag International N.V.
Multiple Myeloma
1 trial -
GEMCITABINE , JNJ-17000139, MITOMYCIN
Janssen-Cilag International N.V.
High-Risk Non-muscle-invasive Bladder Cancer
1 trial -
Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Guselkumab
Janssen-Cilag International N.V.
Juvenile psoriatic arthritis (jPsA), Moderately to severely active ulcerative colitis (UC), Moderately to severely active Crohn's disease (CD)
1 trial -
Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Guselkumab- Solution for infusion- 10 mg/ml
Janssen-Cilag International N.V.
Crohn’s Disease
1 trial -
Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, STELARA 90 mg solution for injection in pre-filled syringe, Placebo for Ustekimumab, Placebo for Guselkumab, STELARA 130 mg concentrate for solution for infusion
Janssen-Cilag International N.V.
Moderately to Severely Active Crohn's Disease
1 trial -
Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL
Janssen-Cilag International N.V.
Psoriatic Arthritis
1 trial -
Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL
Janssen-Cilag International N.V.
Moderate to Severe Plaque Type Psoriasis
1 trial -
Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL
Janssen-Cilag International N.V.
Moderately to Severely Active Ulcerative Colitis
1 trial -
Guselkumab 1 mL PFS Placebo, Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 2 mL PFS Placebo, Guselkumab 0.5 mL Varioject Placebo, Guselkumab, Guselkumab- Solution for infusion- 10 mg/ml
Janssen-Cilag International N.V.
Ulcerative Colitis
1 trial -
Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 1 mL PFS Placebo, Guselkumab 2 mL PFS Placebo
Janssen-Cilag International N.V.
Moderate to Severly Active Ulcerative Colitis
1 trial -
Guselkumab, Placebo 0.5ml equivalent, Guselkumab- Solution for infusion- 10 mg/ml, Placebo 2.0ml equivalent, Guselkumab, Placebo 1.0ml equivalent, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL
Janssen-Cilag International N.V.
Moderately to Severely Active Crohn's Disease
1 trial -
Guselkumab- Solution for infusion- 10 mg/ml, Placebo to Guselkumab, Placebo to Guselkumab solution for injection in pre-filled syringe -100 mg/ml, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Placebo to Guselkumab- Solution for infusion- 10 mg/ml
Janssen-Cilag International N.V.
Fistulizing perianal Crohn's Disease
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources